Axonics® receives fda approval for recharge-free sacral neuromodulation system

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the u.s. food and drug administration (fda) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (snm) implantable neurostimulator (ins). the axonics f15™ recharge-free snm system has the following key attributes: ins type: primary cell batter
AXNX Ratings Summary
AXNX Quant Ranking